VFA
BPMC

Virtus Fund Advisers’s Blueprint Medicines BPMC Stock Holding History

Virtus Fund Advisers’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-147
Closed -$15.8K – 113
2024
Q2 		$15.8K Sell
147
-16
-10% -$1.6K 0.06% 111
2024
Q1 		$15.5K Sell
163
-140
-46% -$12K 0.05% 113
2023
Q4 		$27.9K Sell
303
-215
-42% -$13.9K 0.17% 89
2023
Q3 		$26K Hold
518
– – 0.18% 86
2023
Q2 		$32.7K Hold
518
– – 0.23% 75
2023
Q1 		$23.3K Hold
518
– – 0.16% 92
2022
Q4 		$22.7K Buy
+518
New +$24.8K 0.16% 94
2017
Q4 		$348K Buy
+4,611
New +$324K ﹤0.01% 407

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Virtus Fund Advisers's BPMC Position: Q3 2024 in Review

Virtus Fund Advisers sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 147 shares — an estimated $15.8K sold.

Virtus Fund Advisers first reported a position in BPMC in Q4 2017 and held it in 8 quarters. The position peaked at $348K in Q4 2017. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • Virtus Fund Advisers reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
  • Virtus Fund Advisers sold 147 Blueprint Medicines shares in Q3 2024, an estimated $15.8K.
  • Virtus Fund Advisers first reported a position in Blueprint Medicines in Q4 2017 and held it in 8 quarters.
  • Virtus Fund Advisers's Blueprint Medicines position peaked at $348K in Q4 2017.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Virtus Fund Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.